Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Intra-Cellular Ther (ITCI)

Intra-Cellular Ther (ITCI)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 2,002,347
  • Shares Outstanding, K 80,158
  • Annual Sales, $ 60 K
  • Annual Income, $ -147,720 K
  • 60-Month Beta 1.62
  • Price/Sales 33,626.94
  • Price/Cash Flow N/A
  • Price/Book 2.43
Trade ITCI with:

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 8 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/20
See More
  • Average Estimate -0.87
  • Number of Estimates 3
  • High Estimate -0.76
  • Low Estimate -0.97
  • Prior Year -0.74
  • Growth Rate Est. (year over year) -17.57%

Price Performance

See More
Period Period Low Period High Performance
1-Month
23.23 +1.76%
on 11/02/20
28.77 -17.83%
on 11/09/20
-1.03 (-4.18%)
since 10/30/20
3-Month
17.26 +36.96%
on 09/02/20
33.74 -29.93%
on 09/09/20
+5.43 (+29.82%)
since 08/28/20
52-Week
9.44 +150.42%
on 12/03/19
43.56 -45.73%
on 12/23/19
+13.93 (+143.46%)
since 11/29/19

Most Recent Stories

More News
Intra-Cellular T Set to Possibly Rebound After Yesterday's Selloff of 3.36%

Intra-Cellular T (NASDAQ:ITCI) traded in a range yesterday that spanned from a low of $23.90 to a high of $25.03. Yesterday, the shares fell 3.4%, which took the trading range below the 3-day low of...

ITCI : 23.64 (-5.36%)
Intra-Cellular Therapies to Present at the Evercore ISI 3rd Annual HealthCONx Conference

Intra-Cellular Therapies, Inc. (Nasdaq:ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced that...

ITCI : 23.64 (-5.36%)
Watch for Intra-Cellular T to Potentially Pullback After Gaining 2.43% Yesterday

Intra-Cellular T (NASDAQ:ITCI) traded in a range yesterday that spanned from a low of $26.86 to a high of $27.77. Yesterday, the shares gained 2.4%, which took the trading range above the 3-day high...

ITCI : 23.64 (-5.36%)
Interesting ITCI Put And Call Options For December 18th

Investors in Intra-Cellular Therapies Inc saw new options begin trading this week, for the December 18th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the ITCI...

ITCI : 23.64 (-5.36%)
Intra-Cellular Therapies (ITCI) Reports Q3 Loss, Tops Revenue Estimates

Intra-Cellular (ITCI) delivered earnings and revenue surprises of 17.71% and 12.97%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

ITCI : 23.64 (-5.36%)
Intra-Cellular: 3Q Earnings Snapshot

NEW YORK (AP) _ Intra-Cellular Therapies Inc. (ITCI) on Monday reported a loss of $55.2 million in its third quarter.

ITCI : 23.64 (-5.36%)
Intra-Cellular Therapies Reports Third Quarter 2020 Financial Results and Provides Corporate Update

Positive topline results reported from Study '402, a Phase 3 Study evaluating lumateperone as an adjunctive treatment to lithium or valproate in patients with bipolar depression.

ITCI : 23.64 (-5.36%)
Intra-Cellular Therapies, Inc. to Host Earnings Call

NEW YORK, NY / ACCESSWIRE / November 9, 2020 / Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) will be discussing their earnings results in their 2020 Third Quarter Earnings call to be held on November 9,...

ITCI : 23.64 (-5.36%)
Watch for Intra-Cellular T to Potentially Pullback After Gaining 12.58% Yesterday

Intra-Cellular T (NASDAQ:ITCI) traded in a range yesterday that spanned from a low of $24.14 to a high of $27.00. Yesterday, the shares gained 12.6%, which took the trading range above the 3-day high...

ITCI : 23.64 (-5.36%)
Intra-Cellular Therapies to Host Third Quarter 2020 Financial Results Conference Call and Webcast

Intra-Cellular Therapies, Inc. (Nasdaq:ITCI), a biopharmaceutical company focused on the development of and commercialization of therapeutics for central nervous system (CNS) disorders, today announced...

ITCI : 23.64 (-5.36%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 24% Buy with a Weakest short term outlook on maintaining the current direction.

See More Share

Business Summary

Intra-Cellular Therapies Inc. is a biopharmaceutical company. The company develops drugs for the treatment of neuropsychiatric and neurologic diseases and other disorders of the central nervous system. Its product candidates include ITI-007, ITI-002 and ITI-009 which is in clinical trials. Intra-Cellular...

See More

Key Turning Points

2nd Resistance Point 25.78
1st Resistance Point 24.71
Last Price 23.64
1st Support Level 23.05
2nd Support Level 22.46

See More

52-Week High 43.56
Fibonacci 61.8% 30.53
Fibonacci 50% 26.50
Last Price 23.64
Fibonacci 38.2% 22.47
52-Week Low 9.44

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar